In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement

Based on previous studies by our group in which we demonstrated that dalbavancin loaded in bone cement had good elution capacity for the treatment of biofilm-related periprosthetic infections, we now assess the anti-biofilm activity of dalbavancin and compare it with that of vancomycin over a 3-mont...

Full description

Bibliographic Details
Published in:	Antibiotics
Main Authors:	Mar Sánchez-Somolinos, Marta Díaz-Navarro, Antonio Benjumea, José Matas, Javier Vaquero, Patricia Muñoz, Pablo Sanz-Ruíz, María Guembe
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Subjects:	dalbavancin bone cement polymethylmethacrylate elution biofilm vancomycin
Online Access:	https://www.mdpi.com/2079-6382/12/9/1445

Similar Items

Determination of the Elution Capacity of Dalbavancin in Bone Cements: New Alternative for the Treatment of Biofilm-Related Peri-Prosthetic Joint Infections Based on an <i>In Vitro</i> Study
by: Mar Sánchez-Somolinos, et al.
Published: (2022-09-01)

PMMA Bone Cement: Antibiotic Elution and Mechanical Properties in the Context of Clinical Use
by: Sebastian Philipp von Hertzberg-Boelch, et al.
Published: (2022-07-01)

Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-2: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Acetate Buffer with and Without Divalent Metal Ions
by: Sardar M. Jakaria, et al.
Published: (2024-11-01)

Targeting Dalbavancin Inoculum Effect: Adjunctive Single Dose of Daptomycin
by: Razieh Kebriaei, et al.
Published: (2023-10-01)

Place in therapy of dalbavancin to treat Gram-positive infections in antimicrobial resistance era: an overview
by: Rosario Cultrera
Published: (2024-07-01)

Ototoxicity associated with extended dalbavancin treatment for a shoulder prosthetic joint infection
by: Anna Lange, et al.
Published: (2023-10-01)

Evaluating the Use of Dalbavancin for Off-Label Indications
by: Katherine Taylor, et al.
Published: (2022-04-01)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2022-11-01)

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review
by: Luis Buzón-Martín, et al.
Published: (2021-05-01)

Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series
by: Kailey Ben-Sassi, et al.
Published: (2024-09-01)

Dalbavancin in Bone and Joint Infections: A Systematic Review
by: Sofia Lovatti, et al.
Published: (2023-07-01)

Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series
by: Connor Evins, et al.
Published: (2022-04-01)

Fever for days: A challenging case of dalbavancin-induced fever
by: Mohamed A. Almahal, et al.
Published: (2025-01-01)

The efficacy of dalbavancin and impact on hospitalization and treatment costs in patients with ABSSSI
by: Sergio Carbonara
Published: (2024-07-01)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
by: Simonetti O, et al.
Published: (2021-03-01)

Obliteration of a Large Mandibular Arterio-Venous Malformation with Polymethyl Methacrylate Bone Cement
by: Kerem Öztürk, et al.
Published: (2015-06-01)

Real-world evidence of dalbavancin effectiveness as consolidation therapy in infective endocarditis due to Enterococcus spp.
by: Carmen Hidalgo-Tenorio, et al.
Published: (2025-08-01)

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
by: Lucia Brescini, et al.
Published: (2021-09-01)

Modification of polymethylmethacrylate bone cement with halloysite clay nanotubes
by: Tamer M. Hamdy
Published: (2024-08-01)

Comparison of dalbavancin with standard of care in the management of infective endocarditis: efficacy, safety, and cost analysis
by: Milagros Suárez, et al.
Published: (2024-01-01)

The Effect of Vancomycin and Silver Combination on the Duration of Antibacterial Activity of Bone Cement and Methicillin-Resistant Staphylococcus aureusBiofilm Formation
by: S. A. Bozhkova, et al.
Published: (2021-06-01)

Using Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients: A Real-Life, Single-Center Observational Study
by: Alessandra Oliva, et al.
Published: (2025-01-01)

Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry
by: George Zhanel, et al.
Published: (2024-09-01)

Therapeutic Drug Monitoring of Dalbavancin in Real Life: A Two-Year Experience
by: Dario Cattaneo, et al.
Published: (2023-12-01)

Dalbavancin Use in Bone and Joint Infections
by: Liam P. Alderson, BS, et al.
Published: (2024-12-01)

Evaluation of Dalbavancin Use on Clinical Outcomes, Cost-Savings, and Adherence at a Large Safety Net Hospital
by: Richard Lueking, et al.
Published: (2023-02-01)

Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study
by: Nicholas Rebold, et al.
Published: (2024-03-01)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
by: Giacomo Stroffolini, et al.
Published: (2022-09-01)

Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus
by: Benedict Morath, et al.
Published: (2025-05-01)

Application of cement-augmented pedicle screws in elderly patients with spinal tuberculosis and severe osteoporosis: a preliminary study
by: Shutao Gao, et al.
Published: (2023-08-01)

Elution Kinetics from Antibiotic-Loaded Calcium Sulfate Beads, Antibiotic-Loaded Polymethacrylate Spacers, and a Powdered Antibiotic Bolus for Surgical Site Infections in a Novel In Vitro Draining Knee Model
by: Kelly Moore, et al.
Published: (2021-03-01)

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections
by: Dimitra Dimopoulou, et al.
Published: (2023-09-01)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
by: Andrés Ruiz-Sancho, et al.
Published: (2023-06-01)

Clinical, organizational, and pharmacoeconomic perspectives of dalbavancin vs standard of care in the infectious disease network
by: Daniela Segala, et al.
Published: (2024-07-01)

Bone Cement Emboli after Arthroplasty: Is It Possible? A Case Report and Literature Review
by: Seyyed-Morteza Kazemi, et al.
Published: (2023-08-01)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
by: Leama Ajaka, et al.
Published: (2020-10-01)

Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality
by: Mar de Pablo-Miró, et al.
Published: (2021-10-01)

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience
by: Maria Mazzitelli, et al.
Published: (2022-10-01)

Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment
by: Giammarco Baiardi, et al.
Published: (2025-02-01)

Dalbavancin for Acute Bacterial Skin and Skin Structure Infections in Pediatrics: Insights from Continuation Therapy Experience
by: Sara Maria Scarano, et al.
Published: (2024-04-01)